AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22308295 — intervention group
Group type: EXPERIMENTAL
Intervention: plerixafor 0.24 mg/kg/d in combination with mitoxantrone, etoposide, and cytarabine
Number of subjects: 52
Study 22308295 — intervention group
Group type: EXPERIMENTAL
Intervention: plerixafor
Number of subjects: 52
Study 22308299 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 358
Study 22308299 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 358
Study 22311420 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of aerobic exercise training (7D-EX)
Number of subjects: 13
Study 22312169 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment
Number of subjects: 319
Study 22314007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1333
Study 22315486 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg for 28 days (one cycle) for a total of six cycles or until disease progression
Number of subjects: 36
Study 22316363 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 255
Study 22316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1124
Study 22316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1124
Study 22316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1124
Study 22316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1124
Study 22316567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1124
Study 22316567 — intervention group
Group type: EXPERIMENTAL
Intervention: All medication groups
Number of subjects: 1124
Study 22316571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 29
Study 22317913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cionni-modified capsule tension ring (CTR) implantation with in-the-bag single-piece AcrySof intraocular lens (IOL) implantation
Number of subjects: 41
Study 22318219 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-including cART regimens
Number of subjects: 81
Study 22318666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-value conditional cash transfer ($20 per testing round)
Number of subjects: 2399
Study 22318666 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=1124)
Number of subjects: 2399
Study 22318666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-value conditional cash transfer ($10 per testing round)
Number of subjects: 2399
Study 22318751 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25 to 29.9
Number of subjects: 31231
Study 22318751 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30 or more
Number of subjects: 31231
Study 22318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 31231
Study 22318751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obese postmenopausal participants
Number of subjects: 31231
Study 22318758 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) 400 kcal/d for 7 days
Number of subjects: 14
Study 22319063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute incomplete stent apposition (ISA) segments
Number of subjects: 43
Study 22319063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute incomplete stent apposition (ISA) size (volume or maximum distance per strut)
Number of subjects: 43
Study 22320292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified International Caries Detection and Assessment System II
Number of subjects: 60
Study 22320292 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization sessions
Number of subjects: 60
Study 22321019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 935
Study 22321019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray
Number of subjects: 935
Study 22321019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 935
Study 22321019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 935
Study 22322081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary acetylcholine (ACH) testing
Number of subjects: 304
Study 22322081 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with normal coronary arteries or minimal irregularities)
Number of subjects: 304
Study 22322531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BNP (brain natriuretic peptide) levels categorized into quintiles
Number of subjects: 1139
Study 22322531 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BNP
Number of subjects: 1139
Study 22322531 — intervention group
Group type: COMPARATOR
Intervention: Clinical parameters alone
Number of subjects: 1139
Study 22323303 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy
Number of subjects: 52
Study 22323416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antidiabetes drugs (OADs)
Number of subjects: 12527
Study 22323416 — intervention group
Group type: COMPARATOR
Intervention: No oral antidiabetes drugs (OADs)
Number of subjects: 12527
Study 22323416 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both OAD and non-OAD users)
Number of subjects: 12527
Study 22323451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation in the CCAAT box of the TERC gene promoter
Number of subjects: 0
Study 22323509 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE-DELIRIC model
Number of subjects: 3056
Study 22323509 — intervention group
Group type: COMPARATOR
Intervention: Nurses' and physicians' predictions
Number of subjects: 3056
Study 22325048 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg/week
Number of subjects: 108
Study 22325068 — intervention group
Group type: EXPERIMENTAL
Intervention: High cocoa consumers
Number of subjects: 351
Study 22325068 — intervention group
Group type: COMPARATOR
Intervention: Non-cocoa consumers
Number of subjects: 351
Study 22325357 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (BIBW 2992)
Number of subjects: 5
Study 22325452 — intervention group
Group type: EXPERIMENTAL
Intervention: dHER2 combined with lapatinib (1250 mg/day)
Number of subjects: 12
Study 22326470 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 monotherapy (200mg once daily for 7 days)
Number of subjects: 37
Study 22326470 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC435 monotherapy (200mg once daily for 7 days) followed by PegIFN/RBV
Number of subjects: 37
Study 22326922 — intervention group
Group type: EXPERIMENTAL
Intervention: GVAX combined with 3·0 mg/kg ipilimumab
Number of subjects: 28
Study 22326924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1, 3, 5, and 10 mg/kg) in combination with PSA-Tricom vaccine (2×10^8 plaque-forming units on day 1, followed by 1×10^9 plaque-forming units monthly)
Number of subjects: 30
Study 22326924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and PSA-Tricom vaccine
Number of subjects: 30
Study 22326925 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to chemotherapy
Number of subjects: 70
Study 22327493 — intervention group
Group type: EXPERIMENTAL
Intervention: HibMenCY
Number of subjects: 8500
Study 22327493 — intervention group
Group type: COMPARATOR
Intervention: Hib (control)
Number of subjects: 8500
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vancomycin
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecedent antihistamine use
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 2 years
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous RMS
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin dose ≥ 10 mg/kg
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin concentration ≥ 5 mg/mL
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 546
Study 22327873 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism in the diamine oxidase gene
Number of subjects: 546
Study 22328334 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care for smoking cessation
Number of subjects: 863
Study 22328334 — intervention group
Group type: COMPARATOR
Intervention: Usual care for smoking cessation
Number of subjects: 863
Study 22328495 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous integrated distal capnography (dCap)
Number of subjects: 16
Study 22329763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs) - monophasic OCP (20 μg ethinyl estradiol plus 75 μg gestodene), 21/28 days per cycle, during 6 months
Number of subjects: 49
Study 22329763 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs) with spironolactone 100 mg for 32 patients with severe hirsutism
Number of subjects: 49
Study 22330017 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO (40 g of intrinsically [1-C]phenylalanine-labeled casein protein)
Number of subjects: 16
Study 22330017 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo, no protein)
Number of subjects: 16
Study 22331118 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique
Number of subjects: 55
Study 22331380 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric fructose intake
Number of subjects: 376
Study 22331380 — intervention group
Group type: COMPARATOR
Intervention: Hypercaloric fructose intake
Number of subjects: 376
Study 22331386 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific resistance training for shoulder, neck and arm muscles three times a week (n=282)
Number of subjects: 537
Study 22331386 — intervention group
Group type: COMPARATOR
Intervention: Control group advised to continue normal physical activity (n=255)
Number of subjects: 537
Study 22331386 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific resistance training (n=54 with pain >30 mm VAS at baseline)
Number of subjects: 537
Study 22331386 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=54 with pain >30 mm VAS at baseline)
Number of subjects: 537
Study 22331386 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific resistance training (n=113 with work disability >30 at baseline)
Number of subjects: 537
Study 22331386 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=113 with work disability >30 at baseline)
Number of subjects: 537
Study 22333218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for the first month, then up-titrated to 125 mg twice daily.
Number of subjects: 12
Study 22333218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan treatment
Number of subjects: 12
Study 22334638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral and abdominal MRI
Number of subjects: 58
Study 22334638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral MRI
Number of subjects: 58
Study 22334638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral and/or abdominal MRI
Number of subjects: 58
Study 22335424 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg/m2) plus rituximab (375 mg/m2)
Number of subjects: 10
Study 22336226 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis in patients with ischemic stroke
Number of subjects: 0
Study 22336226 — intervention group
Group type: COMPARATOR
Intervention: No thrombolysis in patients with ischemic stroke
Number of subjects: 0
Study 22336226 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with transient ischemic attack
Number of subjects: 0
Study 22336226 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischemic stroke
Number of subjects: 0
Study 22337718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2)) in combination with CHOP-14
Number of subjects: 20
Study 22339430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 96
Study 22339430 — intervention group
Group type: COMPARATOR
Intervention: Oral olanzapine
Number of subjects: 96
Study 22339949 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF Met allele carriers (n = 20)
Number of subjects: 128
Study 22339949 — intervention group
Group type: COMPARATOR
Intervention: BDNF Val homozygotes (n = 34)
Number of subjects: 128
Study 22339949 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF genotype (Val(66)Met)
Number of subjects: 128
Study 22340331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-driven lidocaine spray (2% lidocaine) with 10 L/min oxygen flow
Number of subjects: 30
Study 22340437 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombolysis (local application of rt-plasminogen activator or urokinase, mechanical thrombosuction, or a combination of both) with heparin before and after the procedure.
Number of subjects: 164
Study 22340437 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (therapeutic doses of heparin).
Number of subjects: 164
Study 22341132 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSense biosensor
Number of subjects: 28
Study 22342057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasphincteric autologous myoblast injections followed by electrical stimulation (ES)
Number of subjects: 38
Study 22342057 — intervention group
Group type: COMPARATOR
Intervention: Preoperative electrical stimulation (ES) cycle
Number of subjects: 38
Study 22342434 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 52
Study 22342434 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin (fos-PHT)
Number of subjects: 52
Study 22342553 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 22342553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22343511 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 88
Study 22343511 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study 22343727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
Number of subjects: 49
Study 22343727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-ABVD
Number of subjects: 49
Study 22344775 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive group (patients with a positive test for myocardial ischaemia)
Number of subjects: 0
Study 22344775 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with a negative test for myocardial ischaemia)
Number of subjects: 0
Study 22344873 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 72
Study 22344873 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopy
Number of subjects: 72
Study 22344964 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-infliximab (IFX) treatment
Number of subjects: 316
Study 22345427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-endurance running exercise
Number of subjects: 11
Study 22347360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 15
Study 22347526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral placement of alloreactive cytotoxic T lymphocytes (alloCTL) with 30,000 IU of human recombinant Interleukin-2 in the cellular infusates.
Number of subjects: 0
Study 22347526 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloreactive cytotoxic T lymphocytes (alloCTL)
Number of subjects: 0
Study 22348003 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab (anti-CD11a)
Number of subjects: 0
Study 22351714 — intervention group
Group type: COMPARATOR
Intervention: Free fructose in isocaloric trials
Number of subjects: 756
Study 22351714 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of fructose in hypercaloric trials (+104 to 250 g/d, +18% to 97% of total daily energy intake)
Number of subjects: 756
Study 22352764 — intervention group
Group type: EXPERIMENTAL
Intervention: NP101 transdermal sumatriptan patch
Number of subjects: 183
Study 22353806 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin (LD) 40 mg m(-2) plus cisplatin 60 mg m(-2) every 21 days
Number of subjects: 38
Study 22354139 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls in the earlier 6 months
Number of subjects: 626
Study 22354139 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 626
Study 22354139 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Activities of Daily Living (BADL)
Number of subjects: 626
Study 22354139 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier fall
Number of subjects: 626
Study 22354139 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence in BADL
Number of subjects: 626
Study 22354206 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-R regimen (pegylated liposomal doxorubicin 4.0 mg/m(2), bortezomib 1.0 mg/m(2), dexamethasone 40 mg, lenalidomide 10 mg daily)
Number of subjects: 40
Study 22354206 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-R regimen
Number of subjects: 40
Study 22356324 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 132
Study 22357361 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure patients receiving both beta-blockers and antagonists of the renin-angiotensin-aldosterone system (n=511)
Number of subjects: 3059
Study 22357361 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure patients receiving neither renin-angiotensin-aldosterone system blockers nor beta-blockers (n=498)
Number of subjects: 3059
Study 22357361 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure patients receiving only one of the recommended classes of medications
Number of subjects: 3059
Study 22357361 — intervention group
Group type: COMPARATOR
Intervention: Patients without congestive heart failure
Number of subjects: 3059
Study 22357361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality rate
Number of subjects: 3059
Study 22357361 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall 1-year mortality rate
Number of subjects: 3059
Study 22357361 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of congestive heart failure
Number of subjects: 3059
Study 22357572 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-minocycline plus active-aspirin
Number of subjects: 120
Study 22357572 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-minocycline plus placebo-aspirin
Number of subjects: 120
Study 22357572 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-minocycline plus active-aspirin
Number of subjects: 120
Study 22357572 — intervention group
Group type: COMPARATOR
Intervention: Placebo-minocycline plus placebo-aspirin
Number of subjects: 120
Study 22357572 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline and aspirin
Number of subjects: 120
Study 22359536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed HD
Number of subjects: 2318
Study 22359536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically unaffected individuals with expanded alleles
Number of subjects: 2318
Study 22359536 — intervention group
Group type: COMPARATOR
Intervention: Individuals without expanded alleles
Number of subjects: 2318
Study 22360576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Number of subjects: 0
Study 22360915 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent prophylactic placement of inferior vena cava filter (CPIVCF)
Number of subjects: 322
Study 22360944 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention and stenting with different drug-eluting coatings and platforms
Number of subjects: 0
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond Blackfan anemia (DBA) patients without bone marrow transplant
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: All cancers combined in DBA
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelodysplastic syndrome
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myeloid leukemia
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon carcinoma
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteogenic sarcoma
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Female genital cancers
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of solid tumor/leukemia
Number of subjects: 608
Study 22362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Median survival in DBA patients
Number of subjects: 608
Study 22362253 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel sequencing of maternal plasma DNA
Number of subjects: 532
Study 22362502 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe autonomic failure (SAF) present
Number of subjects: 174
Study 22362502 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SAF
Number of subjects: 174
Study 22362502 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired LVEF (≤50%)
Number of subjects: 174
Study 22363051 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC score (integrated biomarkers: troponin I, S100β, Glasgow Coma Scale)
Number of subjects: 526
Study 22363051 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC score
Number of subjects: 526
Study 22363051 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Coma Scale
Number of subjects: 526
Study 22363051 — intervention group
Group type: COMPARATOR
Intervention: High S100β
Number of subjects: 526
Study 22363051 — intervention group
Group type: COMPARATOR
Intervention: High troponin
Number of subjects: 526
Study 22363051 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Coma Scale, World Federation of Neurosurgical Societies score, Fisher score
Number of subjects: 526